146665 - Getting to the heart of diabetes: CV risk in patients with type 2 diabetes and CVD - Online Webinar Recording
- : Online
This webinar provides an interactive environment for GPs and their peers to get an update on the latest evidence and guideline recommendations for reducing CV risk in patients with both type 2 diabetes and CVD. The management of type 2 diabetes in patients who have CVD calls for a holistic and multidisciplinary approach. For this webinar we have selected a panel who bring together expertise from a range of backgrounds; general practice, endocrinology, nursing and diabetes education.
Relevance to General Practice
CVD is the leading cause of death and disability for those with type 2 diabetes and they typically experience CVD earlier and with greater severity than people without type 2 diabetes. Guidelines highlight the need for intense pharmacological management to reduce risk of further CV events. However, evidence suggests that almost 40% of patients with both diabetes and established CVD in Australia are not prescribed the combination of medicines recommended for the prevention of CV events. Management of diabetes is also a priority but remains a challenge. These challenges include the need to consider updated guidelines, newly introduced medicines, and the range of patient and medicine factors that need to be considered in patients with CVD. This activity will have a particular focus on pharmacological management of CV risk factors and differentiating between different second- and third-line blood glucose medicines for patients with CVD based on both medicine and patient factors.
- Discuss your practice’s approach to prioritising improvement in the care of patients with type 2 diabetes and established CVD.
- Implement intensive cardiovascular risk factor management when treating patients with both type 2 diabetes and established cardiovascular disease (CVD).
- Select second- and third-line blood glucose-lowering medicines for patients with type 2 diabetes and established CVD based on patient and medicine factors.
- Describe the data from new and emerging cardiovascular outcome trials and its relevance to practice.